Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.

@article{Neufeld2006OralCD,
  title={Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.},
  author={Ellis J. Neufeld},
  journal={Blood},
  year={2006},
  volume={107 9},
  pages={3436-41}
}
For nearly 30 years, patients with transfusional iron overload have depended on nightly deferoxamine infusions for iron chelation. Despite dramatic gains in life expectancy in the deferoxamine era for patients with transfusion-dependent anemias, the leading cause of death for young adults with thalassemia major and related disorders has been cardiac disease from myocardial iron deposition. Strategies to reduce cardiac disease by improving chelation regimens have been of the highest priority… CONTINUE READING
82 Citations
47 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 82 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 47 references

Cost - effectiveness of once - daily oral chelation therapy with deferasirox ( Exjade ( R ) , ICL 670 ) versus infusional deferoxamine in transfusiondependent thalassemic patients [ abstract ]

  • TE Delea, O Sofrygin, SK Thomas, JF Baladi, PD Phatak, TD Coates
  • Blood
  • 2005

Defera - sirox ( Exjade ( R ) , ICL 670 ) demonstrates doserelated effects on body iron levels related to transfusional iron intake in transfusiondependent anemia [ abstract ]

  • P Greenberg, G Dine, A Ganser
  • Blood
  • 2005

Deferasirox (Exjade (R), ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia

  • P Greenberg, G Dine, A Ganser
  • Blood
  • 2005
1 Excerpt

Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox ( Exjade ( ( R ) ) , ICL 670 ) [ abstract ]

  • A Cohen, G Masera, N Zoumbos
  • Blood
  • 2005

Effect of iron intake on control of body iron in patients with thalassemia major treated with deferasirox (Exjade((R)), ICL670)

  • A Cohen, G Masera, N Zoumbos
  • Blood
  • 2005
2 Excerpts

Improved myocardial T 2 * in transfusion dependent anemias receiving ICL 670 ( Deferasirox ) [ abstract ]

  • JB Porter, MA Tanner, DJ Pennell, P Eleftheriou
  • Blood
  • 2005

Similar Papers

Loading similar papers…